查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1781985

單株抗體市場，按來源類型、按生產類型、按適應症、按最終用戶、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Monoclonal Antibody Market, By Source Type, By Production Types, By Indication, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 301 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年單株抗體市場規模價值 2.5028 億美元，2025 年至 2032 年的複合年成長率為 11.92%。

單株抗體市場-市場動態

慢性病盛行率上升和生物工程的進步加速單株抗體市場的成長

癌症和自體免疫疾病等慢性疾病的發生率不斷上升，加劇了人們對單株抗體療法的關注。世界衛生組織報告稱，近年來癌症在全球造成近1,000萬人死亡。生物工程領域的突破使得更精準地靶向疾病機製成為可能，提高了治療效果並改善了患者預後。例如，僅在過去五年中，美國食品藥物管理局 (FDA) 就批准了20多種基於單株抗體的藥物，反映出人們對這些療法日益成長的信任。此外，美國國立衛生研究院 (NIH) 等機構的措施也增加了生物製劑的研究資金，支持創新臨床試驗，並拓展了單株抗體在各種慢性疾病和傳染病中的治療應用。

單株抗體市場－關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 11.92%

根據來源類型細分，預計人源化單株抗體將在 2024 年佔據最大市場佔有率

根據生產類型細分，體外是 2024 年領先的生產類型

根據適應症細分，癌症是 2024 年的主要適應症

按地區分類，北美是 2024 年的主要收入來源

單株抗體市場-細分分析：

全球單株抗體市場根據來源類型、生產類型、適應症、最終用戶和地區進行細分。

根據來源類型，市場分為四類：鼠源單株抗體、嵌合單株抗體、人源化單株抗體、全人源單株抗體。人源化單株抗體因其較低的免疫原性和更高的患者耐受性而佔據主導地位，其次是因其安全性而備受推崇的全人源抗體。嵌合抗體標靶性強，但免疫反應風險較高，而鼠源抗體因免疫原性問題，其應用有限。

根據生產類型，市場分為兩類：體內和體外。體外生產因其在單株抗體生產中具有更高的控制性、可擴展性和一致性而佔據市場主導地位；而體內生產方法則不太常見，主要用於特定的研究目的，儘管其在大規模生產中耗時更長、效率更低。

單株抗體市場-地理洞察

單株抗體市場呈現顯著的地域差異，受區域醫療基礎設施、監管支持和疾病流行程度的影響。北美仍然是一個突出的地區，這得益於美國國家癌症研究所等政府機構的大力資助和先進的生物製藥研究設施，促進了單株抗體療法的快速核准和應用。歐洲緊隨其後，得益於歐洲藥品管理局 (EMA) 的舉措和對個人化醫療不斷增加的投資。在亞太地區，慢性病發病率的上升，加上中國、日本和印度等國醫療體系的改善，正在刺激需求，而旨在提高生物製劑可及性的政府計畫正在獲得發展動力。拉丁美洲和中東的新興市場也在逐步成長，這得益於醫療保險覆蓋範圍的擴大和人們對標靶治療認知的不斷提高。然而，在某些地區，負擔能力和可用性方面的差異仍然是挑戰，影響全球市場擴張的步伐。

單株抗體市場-競爭格局：

單株抗體市場的競爭格局特點是，多家領先的生物製藥公司大力投資研發，以創新和擴大其產品組合。主要參與者經常與學術機構和政府研究機構合作，以加速新療法的發展。本公司專注於透過抗體工程方面的進步（例如雙特異性抗體和抗體-藥物偶聯物）來實現差異化，以滿足尚未滿足的醫療需求。獲得FDA和EMA等機構的監管批准是影響競爭定位的關鍵里程碑。此外，合作夥伴關係和授權協議可以加快市場進入和地理擴張。隨著競爭日益激烈，公司也在努力提高生產效率並降低生產成本，以使治療更容易獲得。對個人化醫療和免疫療法的重視繼續推動策略性投資，創造出一個充滿活力且不斷發展的競爭環境。

最新動態：

2023年9月，KBI Biopharma推出了全新的單株抗體開發平台SureMAB™。 SureMAB™加速了高品質單株抗體的發現和生產，為客戶在各個疾病領域開發新型生物療法提供簡化的工作流程和更短的研發時間。

2025年4月，FDA宣布了一項分階段計劃，以人工智慧建模和類器官測試等先進的、與人類相關的方法取代單株抗體和其他藥物的動物測試要求，旨在提高安全性、加速開發並降低藥物成本和動物使用。

2024年3月，羅氏製藥印度公司推出了全球首個雙特異性單株抗體Vabysmo (faricimab)，用於治療新生血管性老年黃斑部病變和糖尿病黃斑水腫。 Vabysmo獨特地針對兩種疾病途徑，為印度患者提供更好的視力結果和更長的治療間隔。

目錄

第1章：單株抗體市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 單株抗體市場片段（依來源類型）
    • 單株抗體市場依生產類型分類
    • 單株抗體市場片段（按適應症）
    • 單株抗體市場片段（按最終用戶）
    • 單株抗體市場（按國家/地區）
    • 單株抗體市場（按地區）
  • 競爭洞察

第3章：單株抗體主要市場趨勢

  • 單株抗體市場促進因素
    • 市場促進因素的影響分析
  • 單株抗體市場限制
    • 市場限制的影響分析
  • 單株抗體市場機遇
  • 單株抗體市場未來趨勢

第4章：單株抗體產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：單株抗體市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：單株抗體市場格局

  • 2024年單株抗體市佔率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：單株抗體市場－依來源類型

  • 概述
    • 按來源類型分類的細分市場佔有率分析
    • 鼠單株抗體
    • 嵌合單株抗體
    • 人源化單株抗體
    • 全人單株抗體

第 8 章：單株抗體市場 - 按生產類型

  • 概述
    • 按生產類型分類的細分市場佔有率分析
    • 體內
    • 體外

第9章：單株抗體市場－按適應症

  • 概述
    • 按適應症細分市場佔有率分析
    • 癌症
      • 乳癌
      • 大腸直腸癌
      • 肺癌
      • 卵巢癌
      • 其他
    • 自體免疫疾病
    • 發炎性疾病
    • 傳染病
    • 類風濕關節炎
    • 多發性硬化症
    • 牛皮癬
    • 克隆氏症
    • 其他

第 10 章：單株抗體市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院
    • 診斷實驗室
    • 研究機構
    • 製藥和生物技術公司

第 11 章：單株抗體市場-依地域分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美單株抗體主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測，按來源類型
    • 北美市場規模及預測（依生產類型）
    • 北美市場規模及預測（按適應症）
    • 北美市場規模及預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲單株抗體主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模與預測，依來源類型
    • 歐洲市場規模及預測（依生產類型）
    • 歐洲市場規模及預測（按適應症）
    • 歐洲市場規模及預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區單株抗體主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依來源類型）
    • 亞太地區市場規模及預測（依生產類型）
    • 亞太地區市場規模及預測（依適應症）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲單株抗體主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依來源類型）
    • 拉丁美洲市場規模及預測（按生產類型）
    • 拉丁美洲市場規模及預測（按適應症）
    • 拉丁美洲市場規模及預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲單株抗體主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依來源類型）
    • MEA 市場規模及預測（依生產類型）
    • MEA 市場規模及預測（依適應症）
    • MEA 市場規模及預測（依最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：單株抗體產業主要供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • AbbVie
    • Alexion Pharmaceuticals
    • Amgen
    • Bayer Healthcare
    • Biogen
    • Bristol-Myers Squibb
    • Celltrion
    • Eli Lilly
    • Genentech (Roche subsidiary)
    • GlaxoSmithKline (GSK)
    • Johnson & Johnson
    • Merck & Co.
    • Novartis
    • Pfizer
    • Regeneron Pharmaceuticals
    • Roche
    • Samsung Bioepis
    • Sanofi
    • Takeda Pharmaceutical
    • UCB Pharma
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5429

REPORT HIGHLIGHT

The Monoclonal Antibody Market size was valued at US$ 250.28 Million in 2024, expanding at a CAGR of 11.92% from 2025 to 2032.

The Monoclonal Antibody Market refers to the sector involved in the development and commercialization of antibodies engineered to target specific antigens, primarily used in diagnostics, therapeutics, and research applications. The increasing prevalence of chronic diseases like cancer and autoimmune disorders has significantly accelerated demand, with over 70% of biologic therapies in development focusing on monoclonal antibodies. However, high production costs and complex manufacturing processes often limit accessibility, posing challenges for widespread adoption. Advances in bioengineering and personalized medicine present substantial opportunities, enabling the development of more effective and tailored treatments. Additionally, the rising number of clinical trials utilizing monoclonal antibodies, which accounted for nearly 500 ongoing studies globally last year, highlights the expanding scope of this market segment. Despite hurdles, expanding applications in oncology, immunology, and infectious diseases continue to offer promising growth avenues.

Monoclonal Antibody Market- Market Dynamics

Rising prevalence of chronic diseases and advances in bioengineering to accelerate monoclonal antibody market growth

Rising prevalence of chronic diseases such as cancer and autoimmune disorders has intensified the focus on monoclonal antibody therapies, with the World Health Organization reporting that cancer accounted for nearly 10 million deaths worldwide in recent years. Breakthroughs in bioengineering have enabled more precise targeting of disease mechanisms, improving treatment efficacy and patient outcomes. For instance, the U.S. Food and Drug Administration (FDA) approved over 20 monoclonal antibody-based drugs in the past five years alone, reflecting the growing trust in these therapies. Additionally, initiatives by institutions like the National Institutes of Health (NIH) have boosted research funding for biologics, supporting innovative clinical trials and expanding the therapeutic applications of monoclonal antibodies across various chronic and infectious diseases.

Monoclonal Antibody Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 11.92% over the forecast period (2025-2032)

Based on Source Type segmentation, humanized monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Production Types segmentation, in vitro was the leading Production Type in 2024

Based on Indication segmentation, Cancer leading was the leading Indication in 2024

On the basis of region, North America was the leading revenue generator in 2024

Monoclonal Antibody Market- Segmentation Analysis:

The Global Monoclonal Antibody Market is segmented on the basis of Source Type, Production Types, Indication, End-User, and Region.

The market is divided into four categories based on Source Type: Murine Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, and Fully Human Monoclonal Antibodies. Humanized monoclonal antibodies dominate due to reduced immunogenicity and improved patient tolerance, followed by fully human antibodies prized for their safety profiles. Chimeric antibodies offer effective targeting but higher immune response risk, while murine antibodies see limited use due to immunogenicity concerns.

The market is divided into two categories based on Production Types: In Vivo and In Vitro. In vitro production leads the market due to greater control, scalability, and consistency in manufacturing monoclonal antibodies, while in vivo methods are less common, primarily used for specific research purposes despite being more time-consuming and less efficient for large-scale production.

Monoclonal Antibody Market- Geographical Insights

The Monoclonal Antibody Market exhibits significant geographical variation driven by regional healthcare infrastructure, regulatory support, and disease prevalence. North America remains a prominent region due to strong funding from government agencies like the National Cancer Institute and advanced biopharmaceutical research facilities, facilitating rapid approval and adoption of monoclonal antibody therapies. Europe follows closely, supported by initiatives from the European Medicines Agency (EMA) and increasing investments in personalized medicine. In Asia-Pacific, rising incidences of chronic diseases coupled with improving healthcare systems in countries such as China, Japan, and India are fueling demand, while government programs aimed at enhancing access to biologics are gaining momentum. Emerging markets in Latin America and the Middle East are also witnessing gradual growth, driven by expanding healthcare coverage and growing awareness about targeted therapies. However, disparities in affordability and availability remain challenges in some regions, influencing the pace of market expansion globally.

Monoclonal Antibody Market- Competitive Landscape:

The competitive landscape of the Monoclonal Antibody Market is characterized by the presence of several leading biopharmaceutical companies investing heavily in research and development to innovate and expand their product portfolios. Major players often collaborate with academic institutions and government research bodies to accelerate the development of novel therapies. Companies focus on differentiating themselves through advances in antibody engineering, such as bispecific antibodies and antibody-drug conjugates, to address unmet medical needs. Regulatory approvals from authorities like the FDA and EMA are critical milestones that influence competitive positioning. Additionally, partnerships and licensing agreements enable faster market entry and geographic expansion. With increasing competition, companies are also working on improving manufacturing efficiencies and reducing production costs to make treatments more accessible. The emphasis on personalized medicine and immunotherapy continues to drive strategic investments, fostering a dynamic and evolving competitive environment.

Recent Developments:

In September 2023, KBI Biopharma has launched SureMAB(TM), a new monoclonal antibody development platform. SureMAB(TM) accelerates the discovery and production of high-quality monoclonal antibodies, offering streamlined workflows and reduced timelines for clients developing novel biologic therapeutics across various disease areas.

In April 2025, the FDA announced a phased plan to replace animal testing requirements for monoclonal antibodies and other drugs with advanced, human-relevant methods like AI modeling and organoid testing, aiming to improve safety, accelerate development, and reduce drug costs and animal use.

In March 2024, Roche Pharma India launched Vabysmo (faricimab), the world's first bispecific monoclonal antibody, for treating neovascular age-related macular degeneration and diabetic macular edema. Vabysmo uniquely targets two disease pathways, offering improved vision outcomes and extended treatment intervals for Indian patients.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MONOCLONAL ANTIBODY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AbbVie
  • Alexion Pharmaceuticals
  • Amgen
  • Bayer Healthcare
  • Biogen
  • Bristol-Myers Squibb
  • Celltrion
  • Eli Lilly
  • Genentech (Roche subsidiary)
  • GlaxoSmithKline (GSK)
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Regeneron Pharmaceuticals
  • Roche
  • Samsung Bioepis
  • Sanofi
  • Takeda Pharmaceutical
  • UCB Pharma
  • Others

GLOBAL MONOCLONAL ANTIBODY MARKET, BY SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Murine Monoclonal Antibodies
  • Chimeric Monoclonal Antibodies
  • Humanized Monoclonal Antibodies
  • Fully Human Monoclonal Antibodies

GLOBAL MONOCLONAL ANTIBODY MARKET, BY PRODUCTION TYPES- MARKET ANALYSIS, 2019 - 2032

  • In Vivo
  • In Vitro

GLOBAL MONOCLONAL ANTIBODY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Breast cancer
  • Colorectal cancer
  • Lung cancer
  • Ovarian cancer
  • Others
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Psoriasis
  • Crohn's Disease
  • Others

GLOBAL MONOCLONAL ANTIBODY MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical & Biotechnology Companies

GLOBAL MONOCLONAL ANTIBODY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Monoclonal Antibody Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Monoclonal Antibody Market Snippet by Source Type
    • 2.1.2. Monoclonal Antibody Market Snippet by Production Types
    • 2.1.3. Monoclonal Antibody Market Snippet by Indication
    • 2.1.4. Monoclonal Antibody Market Snippet by End-User
    • 2.1.5. Monoclonal Antibody Market Snippet by Country
    • 2.1.6. Monoclonal Antibody Market Snippet by Region
  • 2.2. Competitive Insights

3. Monoclonal Antibody Key Market Trends

  • 3.1. Monoclonal Antibody Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Monoclonal Antibody Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Monoclonal Antibody Market Opportunities
  • 3.4. Monoclonal Antibody Market Future Trends

4. Monoclonal Antibody Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Monoclonal Antibody Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Monoclonal Antibody Market Landscape

  • 6.1. Monoclonal Antibody Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Monoclonal Antibody Market - By Source Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Source Type, 2024 & 2032 (%)
    • 7.1.2. Murine Monoclonal Antibodies
    • 7.1.3. Chimeric Monoclonal Antibodies
    • 7.1.4. Humanized Monoclonal Antibodies
    • 7.1.5. Fully Human Monoclonal Antibodies

8. Monoclonal Antibody Market - By Production Types

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Production Types, 2024 & 2032 (%)
    • 8.1.2. In Vivo
    • 8.1.3. In Vitro

9. Monoclonal Antibody Market - By Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 9.1.2. Cancer
      • 9.1.2.1. Breast cancer
      • 9.1.2.2. Colorectal cancer
      • 9.1.2.3. Lung cancer
      • 9.1.2.4. Ovarian cancer
      • 9.1.2.5. Others
    • 9.1.3. Autoimmune Diseases
    • 9.1.4. Inflammatory Diseases
    • 9.1.5. Infectious Diseases
    • 9.1.6. Rheumatoid Arthritis
    • 9.1.7. Multiple Sclerosis
    • 9.1.8. Psoriasis
    • 9.1.9. Crohn's Disease
    • 9.1.10. Others

10. Monoclonal Antibody Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Diagnostic Laboratories
    • 10.1.4. Research Institutes
    • 10.1.5. Pharmaceutical & Biotechnology Companies

11. Monoclonal Antibody Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Monoclonal Antibody Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Monoclonal Antibody Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Monoclonal Antibody Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Monoclonal Antibody Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Monoclonal Antibody Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Source Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Production Types, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Monoclonal Antibody Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. AbbVie
    • 12.2.2. Alexion Pharmaceuticals
    • 12.2.3. Amgen
    • 12.2.4. Bayer Healthcare
    • 12.2.5. Biogen
    • 12.2.6. Bristol-Myers Squibb
    • 12.2.7. Celltrion
    • 12.2.8. Eli Lilly
    • 12.2.9. Genentech (Roche subsidiary)
    • 12.2.10. GlaxoSmithKline (GSK)
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Merck & Co.
    • 12.2.13. Novartis
    • 12.2.14. Pfizer
    • 12.2.15. Regeneron Pharmaceuticals
    • 12.2.16. Roche
    • 12.2.17. Samsung Bioepis
    • 12.2.18. Sanofi
    • 12.2.19. Takeda Pharmaceutical
    • 12.2.20. UCB Pharma
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us